Achieve Life Sciences to Present at Barclays Global Healthcare Conference
Seattle, WA and Vancouver, BC, March 7, 2025 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a pioneering specialty pharmaceutical company dedicated to the worldwide development and commercialization of cytisinicline for the treatment of nicotine dependence, is thrilled to announce its participation in the upcoming Barclays 27th Annual Global Healthcare Conference. This esteemed event is scheduled to take place at the Loews Miami Beach Hotel in Miami, FL, from March 11-13, 2025.
Company Overview
Achieve Life Sciences is a late-stage pharmaceutical company that has been making significant strides in the development of cytisinicline, a novel, non-nicotine, non-addictive, and orally administered treatment for nicotine dependence. Cytisinicline is an alkaloid derived from the tobacco plant and is believed to work by binding to the alpha-4 beta-2 nicotinic acetylcholine receptors in the brain, effectively blocking nicotine’s effects. The company is currently in late-stage clinical development, with Phase 3 trials underway in the United States and Europe.
Presentation Details
At the Barclays Global Healthcare Conference, Achieve Life Sciences’ leadership team, including CEO Rick Stewart and CFO Paul Rittman, will provide an in-depth update on the company’s business strategy, clinical development progress, and financial outlook. The presentation is scheduled for Wednesday, March 11, 2025, at 1:10 PM ET in the Grand Ballroom of the Loews Miami Beach Hotel. Interested investors and industry professionals are encouraged to attend the presentation in person or to access a live webcast of the event through the Barclays website.
Impact on Individuals
For millions of smokers worldwide, finding an effective and sustainable solution to nicotine addiction remains a significant challenge. Traditional methods, such as nicotine replacement therapies and cold turkey, have limited success rates. Achieve Life Sciences’ cytisinicline, with its novel mechanism of action, offers a promising alternative. By presenting at the Barclays Global Healthcare Conference, the company will have the opportunity to engage with potential investors and industry experts, furthering the conversation around the potential impact of cytisinicline on the lives of individuals battling nicotine addiction.
Impact on the World
Nicotine addiction is a global health concern, with the World Health Organization estimating that approximately 1.1 billion smokers worldwide will die prematurely due to tobacco use. The economic burden of tobacco-related illnesses is substantial, with the World Bank reporting that low- and middle-income countries spend over $1.4 trillion on healthcare costs related to tobacco use. Achieve Life Sciences’ cytisinicline, if successful, could significantly reduce the number of smokers worldwide and result in substantial cost savings for healthcare systems. The presentation at the Barclays Global Healthcare Conference will serve as an essential step in raising awareness about the potential impact of this innovative treatment on public health and healthcare economics.
Conclusion
Achieve Life Sciences’ participation in the Barclays 27th Annual Global Healthcare Conference represents a pivotal moment for the company as it continues to advance its mission to develop and commercialize cytisinicline as a treatment for nicotine dependence. The presentation offers an opportunity for investors and industry experts to gain a deeper understanding of the company’s progress, strategy, and financial outlook. Furthermore, the potential impact of cytisinicline on individuals battling nicotine addiction and the global health and economic implications make this an essential conversation for the healthcare community. We invite all interested parties to join us at the conference or to access the live webcast to learn more about Achieve Life Sciences and its groundbreaking work in the field of nicotine dependence treatment.
- Achieve Life Sciences to present at Barclays 27th Annual Global Healthcare Conference
- CEO Rick Stewart and CFO Paul Rittman to discuss business strategy, clinical development progress, and financial outlook
- Presentation scheduled for Wednesday, March 11, 2025, at 1:10 PM ET
- Live webcast available through the Barclays website
- Cytisinicline, a non-addictive and orally administered treatment for nicotine dependence, offers a promising alternative to traditional methods
- Impact on individuals: potential to significantly reduce number of smokers and improve lives
- Impact on the world: substantial cost savings for healthcare systems and reduction in tobacco-related illnesses
